STAT+: FDA revisits a rare cancer treatment it rejected a few months ago
Stat News • 5/7/2026
Summary
The FDA is revisiting a rare cancer treatment that it previously rejected a few months ago. The news also includes information about secret drug pricing deals and a virtual AI cancer clinic, along with other biotech updates from The Readout.
Advertisement
Lindy Score Breakdown (V4.2)
6d
Age
1
Sources
from cluster
150
Hours Since Seen
Final Score2/100
CategoryAntiLindy
StatusActive
Recency Multiplier11% (0.5^150/48)
Hero EligibleYes
Score BreakdownRisk 50
Source Reputation: Low-trust source (4/20 pts)
Consensus: Single source - no independent confirmation yet
Age: 6 days - proven survivor
Stories gain Lindy status through source reputation, network consensus, and time survival.
Related Stories
Breaking Similar stories
STAT+: Astellas treatment offers new hope to a devastated rare disease community
Stat News • 2 days ago
STAT+: Five years after disaster, a rare disease community gets new chance at treatment
Stat News • 2 days ago
STAT+: Scientists link boy’s tumor to gene therapy viruses, in rare finding
Stat News • Today
STAT+: STAT examines America’s deadliest drug
Stat News • 1 day ago
STAT+: Drug meant to make gene therapy safer may also make it less effective
Stat News • Today
STAT+: Hims’ sales miss as telehealth competition grows
Stat News • 1 day ago
STAT+: Pharmalittle: We’re reading about FDA’s Makary resigning, a Lilly weight loss drug trial, and more
Stat News • Today
STAT+: In the battle of sepsis algorithms, performance alone doesn’t predict victory
Stat News • 1 day ago
STAT+: Why Marty Makary was the worst FDA commissioner in 25 years
Stat News • 1 day ago
STAT+: AI medical devices’ dirty FDA secret
Stat News • Today
